Modified Antibody
Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
1 . A method of treating multiple myeloma or lymphoma in a patient in need thereof, the method comprising administering to the patient, a recombinant antibody-based molecule comprising two targeting units and two antigenic units connected through a dimerization motif, or a nucleic acid encoding said recombinant antibody-based molecule.
2 - 6 . (canceled)
7 . The method of claim 1 , wherein at least one targeting unit is a ligand.
8 . (canceled)
9 . The method of claim 7 , wherein said ligand is a chemokine.
10 . The method of claim 9 , wherein said chemokine is RANTES or MIP-1α.
11 - 13 . (canceled)
14 . The method of claim 1 , wherein the targeting units have the ability to target antigen presenting cells (APC).
15 - 17 . (canceled)
18 . The method of claim 1 , wherein the antigenic unit(s) is/are an antigenic scFv.
19 . The method of claim 18 , wherein the antigenic scFv is derived from a monoclonal Ig produced by myeloma or lymphoma.
20 - 26 . (canceled)
27 . The method of claim 1 , wherein the dimerization motif comprises a hinge region and an immunoglobulin domain.
28 . (canceled)
29 . The method of claim 27 , wherein the hinge region has the ability to form one or several covalent bonds.
30 . (canceled)
31 . The method of claim 27 , wherein the immunoglobulin domain is a carboxyterminal C domain, or a sequence that is substantially homologous to said C domain.
32 . (canceled)
33 . The method of claim 27 , wherein the immunoglobulin domain has the ability to homodimerize.
34 - 35 . (canceled)
36 . The method of claim 1 , comprising administering the nucleic acid to the patient to induce production of the recombinant antibody-based molecule.
37 . (canceled)
38 . A recombinant antibody-based molecule comprising two targeting units and two antigenic units connected through a dimerization motif, or a nucleic acid encoding said recombinant antibody-based molecule.
39 - 42 . (canceled)
43 . The recombinant molecule of claim 38 , wherein at least one targeting unit is a ligand.
44 . (canceled)
45 . The recombinant molecule of claim 43 , wherein said ligand is a chemokine.
46 . (canceled)
47 . The recombinant molecule of claim 45 , wherein said chemokine is MIP-1α.
48 - 57 . (canceled)
58 . The recombinant molecule of claim 38 , wherein at least one antigenic unit is derived from a bacterium.
59 . The recombinant molecule of claim 58 , wherein the bacterium derived antigenic unit(s) is/are a tuberculosis antigen.
60 . The recombinant molecule of claim 38 , wherein at least one antigenic unit is derived from a virus.
61 - 75 . (canceled)
76 . A pharmaceutical composition comprising a recombinant molecule of claim 38 and a physiologically acceptable diluent or carrier.
77 - 82 . (canceled)